Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Oncogenes and glial tumors.

D Watkins1, G A Rouleau

  • 1Centre for Research in Neuroscience, McGill University, Montreal, Canada.

Revue Neurologique
|January 1, 1992
PubMed
Summary

Activation of oncogenes and inactivation of tumor suppressor genes drive human glioma development. Key genes include epidermal growth factor receptor (EGFR) and p53, crucial for understanding glioma genesis and progression.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Posttranslational modifications & lithium's therapeutic effect-Potential biomarkers for clinical responses in psychiatric & neurodegenerative disorders.

Neuroscience and biobehavioral reviews·2021
Same author

Radical resection of large metastatic non-functioning pancreatic neuroendocrine carcinoma complicated by splenic vein thrombosis and sinistral portal hypertension.

International journal of surgery case reports·2021
Same author

Corrigendum to 'Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE)': Annals of Oncology, Volume 31, Issue 1, 2020, Pages 79-87.

Annals of oncology : official journal of the European Society for Medical Oncology·2020
Same author

Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE).

Annals of oncology : official journal of the European Society for Medical Oncology·2020
Same author

Alpha galactosidase A activity in Parkinson's disease.

Neurobiology of disease·2018
Same author

Investigating the feasibility of tumour molecular profiling in gastrointestinal malignancies in routine clinical practice.

Annals of oncology : official journal of the European Society for Medical Oncology·2018

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Human gliomas arise from complex genetic alterations.
  • Both oncogene activation and tumor suppressor gene inactivation are implicated in glioma genesis and progression.

Purpose of the Study:

  • To review the roles of dominant oncogenes and tumor suppressor genes in human glioma development.
  • To highlight key genetic factors involved in glioma genesis and progression.

Main Methods:

  • Review of numerous studies on glioma genetics.
  • Analysis of gene amplification, rearrangement, and deletion data.
  • Identification of specific oncogenes and tumor suppressor genes.

Main Results:

  • Epidermal growth factor receptor (EGFR) activation via gene amplification/rearrangement is a well-established oncogene in gliomas.
  • Evidence suggests ros oncogene activation and other dominant oncogenes may be involved.
  • Tumor suppressor gene inactivation on chromosomes 17p (likely p53), 10, 9p, and 22 is implicated in glioma development.

Conclusions:

  • Genetic alterations, including oncogene activation and tumor suppressor gene inactivation, are fundamental to human glioma development.
  • Further research is needed to identify all relevant genes and their interactions in gliomas.

Related Experiment Videos